La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Nanexa Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Nanexa ha un patrimonio netto totale di SEK93.0M e un debito totale di SEK1.8M, che porta il suo rapporto debito/patrimonio netto a 2%. Le sue attività totali e le sue passività totali sono rispettivamente SEK123.9M e SEK30.9M.

Informazioni chiave

1.8%

Rapporto debito/patrimonio netto

SEK 1.54m

Debito

Indice di copertura degli interessi	n/a
Contanti	SEK 41.31m
Patrimonio netto	SEK 87.00m
Totale passività	SEK 27.45m
Totale attività	SEK 114.45m

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

How Much Does Nanexa's (STO:NANEXA) CEO Make?

Dec 09

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( SEK62.3M ) di NANEXA superano le sue passività a breve termine ( SEK29.1M ).

Passività a lungo termine: Le attività a breve termine di NANEXA ( SEK62.3M ) superano le sue passività a lungo termine ( SEK1.8M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: NANEXA ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di NANEXA si è ridotto da 13.5% a 2% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: NANEXA ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: NANEXA ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 26.7 % ogni anno

Nanexa Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Nanexa AB (Publ) Announces That the First Patient in the Third Dose Group with Their Long-Acting Depot Formulation of the Glp-1 Analog Liraglutide Has Been Dosed

New minor risk - Profitability

Second quarter 2024 earnings released: kr0.04 loss per share (vs kr0.16 loss in 2Q 2023)

Nanexa's Phase I Trial of NEX-22 in Type 2- Diabetes Progresses with Next Dose Group According to Plan

Nanexa AB (publ) Announces Chief Financial Officer Changes

Nanexa AB (Publ) Announces That First Patient Dosed in Nanexa's Phase I Trial of NEX-22 in Type 2 Diabetes

New major risk - Financial position

Nanexa AB Receives Approval for NEX-22 Clinical Study

Nanexa AB (publ) Elects Hanna Tilus as Members of the Board

First quarter 2024 earnings released: kr0.02 loss per share (vs kr0.14 loss in 1Q 2023)

Nanexa AB (publ) Announces Approval of Clinical Trial Application for NEX-22 Study Delayed

New major risk - Shareholder dilution

Full year 2023 earnings released: kr1.09 loss per share (vs kr1.16 loss in FY 2022)

Nanexa AB (publ), Annual General Meeting, May 15, 2024

Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA

Consensus revenue estimates increase by 32%

New minor risk - Financial position

Third quarter 2023 earnings released: kr0.11 loss per share (vs kr0.24 loss in 3Q 2022)

Nanexa AB Completes Clinical Phase I Study with NEX-20

Consensus EPS estimates upgraded to kr0.42 loss

Price target decreased by 19% to kr4.95

Second quarter 2023 earnings released: kr0.16 loss per share (vs kr0.32 loss in 2Q 2022)

Nanexa AB Confirms Continued Positive Results from A New Preclinical Study of Nex-22

Nanexa AB (Publ) Approves Election of Jakob Dynnes Hansen as Member of the Board

Nanexa AB (Publ) Announces Urban Paulsson and Bengt Gustavsson Declines Re-Election

First quarter 2023 earnings released: kr0.14 loss per share (vs kr0.24 loss in 1Q 2022)

Nanexa AB (publ) to Report Q1, 2023 Results on May 04, 2023

Full year 2022 earnings released: kr1.16 loss per share (vs kr1.01 loss in FY 2021)

Nanexa AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Nanexa Starts the Phase 1 Study of NEX-20 According to Plan

Price target decreased to kr6.00

No longer forecast to breakeven

Nanexa Receives Approval to Start Clinical Trial with NEX-20

Third quarter 2022 earnings released: kr0.24 loss per share (vs kr0.18 loss in 3Q 2021)

Nanexa AB (Publ) and Vitrivax, Inc Reach Agreement in Principle

Nanexa AB (Publ) Launches NEX-22 Product Project to Address Huge Market

Nanexa AB (publ) to Report Nine Months, 2022 Results on Oct 25, 2022

Second quarter 2022 earnings released: kr0.32 loss per share (vs kr0.33 loss in 2Q 2021)

Nanexa AB (publ) Receives Extended GMP-Certificate for the New Pilot Plant

Less than half of directors are independent

Nanexa AB (publ), Annual General Meeting, Jun 09, 2022

Nanexa Receives Grant from VINNOVA for Study with Monoclonal Antibodies

Forecast to breakeven in 2023

Price target decreased to kr7.00

Full year 2021 earnings: EPS and revenues miss analyst expectations

Nanexa AB Announces That the Company's Preclinical Investigation

Price target decreased to kr7.00

High number of new directors

Nanexa Announces Inclusion of Patients in its Phase I Study with NEX-18

Second quarter 2021 earnings released

First quarter 2021 earnings released: kr0.29 loss per share (vs kr0.22 loss in 1Q 2020)

Nanexa Appoints Jonas Fransson as Head of Pharmaceutical Development

New 90-day low: kr10.20

Full year 2020 earnings released: kr1.09 loss per share (vs kr0.88 loss in FY 2019)

Nanexa AB to Report Q1, 2021 Results on May 06, 2021

How Much Does Nanexa's (STO:NANEXA) CEO Make?

New 90-day low: kr10.25

Third quarter 2020 earnings released: kr0.18 loss per share

New 90-day high: kr13.40

New 90-day high - kr13.35

First half earnings released

New 90-day high - kr11.80

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane